BerGenBio ASA is a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs. Their lead compound, bemcentinib, is a highly selective inhibitor of the receptor tyrosine kinase AXL, which is being developed for 1L STK11 mutated Non-Small Cell Lung Cancer (NSCLC) and severe respiratory infections. The company's focus is on advancing bemcentinib to address the high unmet medical needs in these areas.

BerGenBio ASA

PR Newswire is the global leader in innovative communications and marketing services that enable marketers, corporate communicators, sustainability officers, investor relations officers and many more to leverage content to connect and engage with their target audiences globally and drive demand across all channels. Having pioneered the commercial news distribution industry over 60 years ago, PR Newswire today provides end-to-end solutions to produce, optimise and target content – from rich media microsites to high impact video to multimedia press releases – then distribute content and measure results across traditional, digital, mobile and social channels. Combining the world’s largest multi channel distribution network with the most comprehensive workflow tools and platforms, PR Newswire enables the world’s businesses to drive demand and engage opportunity everywhere it exists.  PR Newswire serves tens of thousands of clients from offices in the Americas, EMEA and APAC, and is a UBM plc company.

UK:CO:PRNEWSWIRE

BerGenBio ASA

Financials Not Available